Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject.
The revised NIA-AA diagnostic criteria for Alzheimer's disease (AD) and mild cognitive impairment (MCI) due to AD make use of amyloid pathology and neurodegeneration biomarkers which increase the diagnostic confidence in the majority of patients. However, in daily praxis, cases with conflicting biomarker constellations occur. A MCI subject underwent neuropsychological testing supplemented by FDG and amyloid PET/MRI as well as CSF sampling. In this subject, the biomarkers of Abeta deposition were negative. [18F]FDG PET, however, showed an AD-typical hypometabolism. Further studies are required to determine frequency and relevance of cases with neurodegeneration-first biomarker constellations to improve our understanding on pathogenesis and diagnosis of AD.
Human Diseases: Cognitive disorder, Alzheimer's disease
Citation: J Alzheimers Dis. 2015;47(3):539-43. doi: 10.3233/JAD-150163.
Date Published: 25th Sep 2015
Registered Mode: by PubMed ID
Views: 3591
Created: 9th May 2019 at 14:34
Last updated: 7th Dec 2021 at 17:58
None